EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
about
The Autoimmune EcologyVaccination of Adult Patients with Systemic Lupus Erythematosus in PortugalVaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesEffects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseasesUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Rituximab in autoimmune diseasesFrequently asked questions on seven rare adverse events following immunization.Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?Seasonal influenza vaccination of high-risk adults.Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis.Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.Influenza and pneumococcal vaccination in patients with rheumatoid arthritis in comparison with age- and sex-matched controls: results of a claims data analysis.Infection in systemic lupus erythematosus, similarities, and differences with lupus flare.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeAvailable influenza vaccines: immunization strategies, history and new tools for fighting the disease.The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effectsRisk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).Vaccinations in paediatric rheumatology: an update on current developments.The Diagnosis and Treatment of Systemic Lupus ErythematosusPneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyPneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners.Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA).Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.A literature review on the patients with autoimmune diseases following vaccination against infections.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.Herpes Zoster Meningitis Complicating Combined Tocilizumab and Cyclosporine Therapy for Adult-Onset Still's Disease.Assessment of the level of vaccine-induced anti-HBs antibodies in children with inflammatory systemic connective tissue diseases treated with immunosuppression.Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home.Evaluation of Reference Centers for Special Immunobiologicals implementation.Herpes zoster vaccination in SLE: a pilot study of immunogenicity.Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors.
P2860
Q26747427-6BAE8A02-841C-452E-B59D-47DFC7B83C2CQ26749096-05DB237A-396A-4FE7-AF14-363294B869ADQ26796420-58F322D5-32F0-4636-9D3D-2E9292BF8177Q26825440-6D960E14-B12F-4124-A7CB-25E0EC9B20B4Q27691388-5BF822D6-EED5-40D3-B20B-F2BB38D3B243Q28076091-04108531-52E9-44FA-BE67-8DD16391C9AFQ30234430-E0E6E85D-F470-4F85-A8B7-5FF529F2C735Q30363962-115142A6-192D-49B4-8F30-5BD77B0072A1Q30387979-D1B49EA0-D1FD-42EA-94C2-607E73145FA7Q30388063-3BADB97D-9AFF-4FF4-B421-1F92757D81D8Q30420493-22581704-FC4C-4EE9-8A71-FE2D936075D6Q30420964-A88B4C42-2FC9-4E15-B533-12477E9E1273Q31081624-3521B0C0-B70E-4B09-ACEB-0260D3BA1CC4Q31111950-31A25A8D-A732-4CF3-AAE4-B9FB188443DAQ33690722-236F1498-EB47-4180-8D4D-9227FCFC46FCQ33731711-167DCFD8-3B25-434F-B65D-5C9F9555929DQ34532079-1B88AA32-22E4-4934-82A5-FBAD541CE898Q34597321-C83A42AD-4ACE-4444-8F68-4117E9047BC7Q35237316-B8F32D3D-3640-4D06-B1A7-99A539D120C5Q35350912-77DB24C1-D625-49D0-B69A-9A78B9E5D74DQ35666223-82C1D917-3173-46AD-8FB5-F7123ACA9C59Q35692998-082A0B1B-5586-43FC-BB9A-46E892398BC4Q35782767-316C7F2B-F4C7-4A85-A219-CF61565BC1C6Q35782786-C2181DAB-AD9F-472F-8072-0AA96BC4DA86Q35792458-B91EF5F0-DB70-4BC9-AF11-85472378D02FQ35907835-27417F7C-AE79-425C-A238-C4C63D631B70Q36005210-D8FC8A37-B2ED-4F6D-B59F-54BA1DD18057Q36031285-37098AE9-B034-48A7-B2B7-7F7010AED456Q36255747-64F6829A-1DC2-449B-8467-41586C464B7DQ36302245-0B0547CD-51DA-4059-B829-192856EB40C1Q36644797-3BC65DF1-1AC4-44E4-B014-D904670816D8Q36677277-B44AB14A-A476-42F2-AB5C-E52C06251C71Q36761926-BBD6CA24-03E9-4FD8-BF67-E37C17C59686Q36764586-9B738B0C-ED1E-43B4-9E19-72149ABAFB4FQ36842326-098BAF9A-4ADE-4633-A339-AF66A10F5AFBQ37146476-EE740E2C-53E3-46C1-B4A3-BAC8A6D31791Q37211401-2C9DDCEB-87D7-4359-BBF2-6A78BAC559B1Q37402728-26CE1E4B-AC7A-4819-83C3-3738420C6543Q37465556-59B0CEB8-4672-4520-9E05-A2041B9C309CQ37487299-A600F7A2-BE1E-4428-BD81-2A22F3342D70
P2860
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en-gb
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@nl
type
label
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en-gb
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@nl
prefLabel
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en-gb
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@nl
P2093
P50
P356
P1476
EULAR recommendations for vacc ...... flammatory rheumatic diseases.
@en
P2093
C G M Kallenberg
D R W Jayne
L Stojanovich
M Dougados
N M Wulffraat
S van Assen
P304
P356
10.1136/ARD.2010.137216
P407
P50
P577
2010-12-03T00:00:00Z
P5875
P6179
1031365398